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This study aimed to comprehensively assess epidemiologic
evidence on the relation between obesity and kidney disease
(KD). From 247 retrieved articles via PubMed (1980–2006), 25
cohorts, 3 cross-sectional, and 19 case–control studies met
inclusion criteria. Related data were extracted using a
standardized protocol. We estimated the pooled relative risk
(RR) and 95% confidence interval (95% CI) of KD for each
body mass index (BMI) category compared with normal
weight using meta-analysis models. Population attributable
risk was also calculated. Compared with normal-weight
individuals (18.5oBMIo25), overweight individuals
(25pBMIo30) had elevated risk for KD (RR¼ 1.40; 95% CI
1.30–1.50); obese individuals were at much higher risk
(RR¼ 1.83 (1.57–2.13)). Obesity in women was associated
with a higher risk than in men (RR¼ 1.92 (1.78–2.07) vs 1.49
(1.36–1.63); Po0.001). Results from cohort studies in patient
populations and cross-sectional and case–control studies all
indicated a positive association between BMI and risks for KD
outcomes. We estimated that 24.2% and 33.9% of KD cases
among US men and women, respectively, and in
industrialized countries, 13.8% in men and 24.9% in women,
could be related to overweight and obesity. Obesity increases
the risk for KD in the general population, and the association
appears to be stronger in women than in men. Obesity
adversely affects the progress of KD among patients with
kidney-related diseases.
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Obesity is known to increase the risk of a number of chronic
diseases.1–3 The growing worldwide obesity epidemic has
become a public health crisis, affecting many countries. In the
United States, obesity is now the second leading cause of
preventable disease and death, surpassed only by smoking.
There has been increasing interest on the role of the obesity
epidemic on risk of kidney disease (KD)4–6 in part because of
the concurrent dramatic rise in the prevalence of end-stage
renal disease (ESRD),7 which has more than doubled in the
past decade.8 The number of patients living with ESRD is
projected to reach 650 000 by 2010 in the United States,
accounting for $28 billion in medical care expenditures.9
Interventions to prevent KD and its progression to
ESRD have the potential to save many lives as well as
decrease health-care costs.10 Identifying modifiable risk
factors for KD is critical in order to develop effective,
population-based strategies.11–13 As obesity is closely asso-
ciated with the two most common causes of ESRD,
namely type II diabetes and hypertension, it may increase
the risk of ESRD.14–17 Available data suggest that the
incidence of some KD outcomes vary greatly across different
regions of the world that have different prevalence of obesity,
suggesting that obesity may be an important risk factor for
KD.18–22 For example, the incidence of renal cell cancer
(RCC) varies more than 10-fold in different regions of the
world. It is the highest in North America, and lowest in
Asia.23 Two major obstacles to prospectively studying risk
factors for KD are the low incidence and long latency period
of many forms of KD.24 Despite these obstacles, increasing
numbers of studies suggest that obesity is an important risk
factor for KD.
Previous reviews of the association between obesity and
KD14,25–27 have either focused on a single disease25,27 or have
not included recent large prospective studies.14,25–27 A
thorough systematical and quantitative assessment of
published findings is not available. This study aimed
to comprehensively assess epidemiologic evidence on
the relation between obesity and KD outcomes. We
first performed a systematic review of studies that have
examined the association in adults, and then conducted a
meta-analysis based on cohort studies conducted in the
general population.
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RESULTS
The association between obesity and KD: systematic review
Findings of prospective cohort studies in the general
population. Table 1 summarizes the main characteristics
and findings of 19 eligible cohorts described in 16 studies.
The majority of the cohorts (n¼ 12) were from the United
States, four were from Europe, two from Japan, and one from
Korea. The number of subjects included in these studies
varied considerably, ranging from 2585 to 2 001 719.5,36 Five
cohorts included only men, and another four cohorts
included only women. The follow-up periods ranged from
3 to 35 years (median¼ 15 years). Overall, these studies
indicate that obesity increased the risk for KD, including
chronic kidney disease (CKD),5,28 ESRD,6,30 kidney stones,31
kidney cancer,20,32 and RCC.34–37
The recent study reported by Hsu et al.,6 one of the most
important cohort studies, assessed the impact of increased
body mass index (BMI) on risk of ESRD based on historical
cohort data collected in a large, integrated health-care
delivery system in California (n¼ 320 252) between 1964
and 1985.6 A total of 1471 cases of ESRD occurred during
8 347 955 person-years of follow-up. A strong dose–response
relationship was found between baseline BMI and the risk of
ESRD. Compared with normal-weight individuals, the
adjusted relative risks (RRs) were 1.87 (1.64–2.14), 3.57
(3.05–4.18), 6.12 (4.97–7.54), 7.07 (5.37–9.31) for overweight,
class I, II, and III obesity, respectively.
Some of these cohort studies detected a gender difference
in the association between obesity and KD. The two recent
large-scale cohort studies conducted by Taylor et al.,31 from
Harvard University, and Iseki et al.,30 in Japan, provided
useful insights into the gender difference. Taylor et al. found
that obesity increased the risk of kidney stone formation in a
prospective study of three large cohorts (the Health
Professionals Follow-up Study, the Nurses’ Health Study I,
and the Nurses’ Health Study II), and the association was
stronger in women than in men. In contrast, Iseki et al.30
found that higher BMI at baseline increased the risk of ESRD
after 17 years follow-up in men, but not in women.
Similar findings were also observed in other studies
conducted in Europe32,34 and in the United States.20,38,39
Flaherty et al.39 found that BMI at baseline was positively
associated with the risk of RCC in women (Po0.05), but not
in men (P40.05). In contrast, Iseki et al.30 found that higher
BMI at baseline increased the risk of ESRD after 17 years
follow-up in men, but not in women. In summary, obesity
increases the risk for developing KD in the general
population, but gender differences might exist in the
associations between obesity and different KD outcomes.
The association between obesity and secondary KD-related
outcomes: prospective data from patient populations. The
characteristics and main findings of 6 cohort studies
conducted in patient populations are presented in Table 2.
In four of the studies, the patients had kidney-related disease
or conditions (e.g., immunoglobulin A nephropathy, renal
transplantation), and the remaining two followed patients
with hypertension.41 The number of subjects ranged from
162 to 51 92743,45 and the mean follow-up period was 1–11
years. Most adjusted for important potential confounders.
In general, these studies found that, overweight or obese
KD patients had worse outcomes than their normal-weight
counterparts. In addition, some studies indicate a J- or
U-shaped association between baseline BMI and KD
outcomes (e.g., pre-transplantation BMI and graft loss).
High BMI at the time of first renal biopsy was also an
independent risk factor for chronic renal failure (CRF).43
Ducloux et al.44 found that post-transplantation weight gain
in patients with renal transplantation significantly increased
the risk of graft loss. Finally, Kramer et al.41 followed 5897
hypertensive patients for 5 years, and found that overweight
and obesity were associated with a 20–40% increased risk for
the development of chronic KD.
Evidence from cross-sectional and case–control studies. The
main findings of 3 eligible cross-sectional studies and 19
case–control studies of the association between obesity and
KD are presented in Appendix 1. Most of these case–control
studies examined the association between obesity and RCC,
and were included in a previous meta-analysis.26 Overall, the
main findings were consistent with those from the above
cohort studies in the general population.
Association between body fat distribution and KD. We
identified nine published studies that provided data for
examining whether overall obesity assessed using BMI or
central obesity assessed using waist circumference (WC) or
waist–hip ratio is a stronger predictor of KD.31,34,69–75 Some
of them were conducted in the general populations and some
among patients, but only two were prospective cohort studies
in the general populations.31,34 In general, the findings were
mixed. Some suggest that BMI is a stronger predictor of KD
risk, while others suggest central obesity is better. For
example, Pischon et al.34 examined the association between
baseline anthropometric measures and RCC risk among
348 550 subjects from eight European countries. During a 6-
year follow-up, 287 cases of RCC were identified. Among
women, an increased risk of RCC was conferred by weight
(RR in highest vs lowest quintile: 2.13 (1.16–3.90)), BMI
(2.25 (1.14–4.44)), WC (1.67 (0.94–2.98)), and hip circum-
ference (2.30 (1.22–4.34)). Waist and hip circumference were
no longer significant after controlling for weight, suggesting
that general adiposity is a more important determinant
of risk in women. Among men, hip circumference (0.44
(0.20–0.98)) was inversely related to RCC risk after accoun-
ting for body weight, suggesting that fat distribution
pattern may be more predictive of RCC risk than overall
obesity in men.
The recent Harvard study shows that BMI and WC were
positively associated with the risk for kidney stone formation
in men and women.31 The multivariable RR for men with a
WC greater than 109 cm compared with men with a
WCo86 cm was 1.48 (1.13–1.93). The multivariable RRs
for older and younger women with a WC4102 cm compared
with women with a WCo79 cm were 1.71 (1.40–2.10) and
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Table 1 | Characteristics and main findings of 19 included cohort studies (from 16 studies) on the association between obesity
and kidney disease in general populations, by outcome and country of data collection
Reference Country
N, age
(years)
Follow-up
(years)
Exposure assessment:
obesity/overweight
(BMI: kg m2)
BMI
M/Ra Outcome
Main findings: RR
(or OR) and 95% CI Comments
Stengel et al.28 USA (NHANES II
follow-up)
9082, 30–74 12–16 Underweight: o18.5
Normal weight:b
BMI 18.5–24.9
Overweight:25–29.9
Obesity: 30–34.9
Morbidly obesity:
BMIX35
M CKD 1.3 (0.5–3.1) for underweight
0.9 (0.5–1.5) for overweight
1.0 (0.6–1.8) for obesity
2.3 (1.1–4.9) for morbidly
obesity
(1) Morbidly obesity
increased risk of CKD
(2) Confounders adjusted for
age, gender, ethnicity,
smoking, alcohol use, and
exercise
Fox et al. 5 USA (FOS) 2585, 28–62 18.5 BMI per 1SD M CKD OR: 1.23 (1.08–1.41) for
BMI per 1 s.d.
Hypertension and cholesterol
level did not enter the
multivariate model
(1) Higher BMI increased risk
of CKD
(2) Confounders adjusted for
gender, age, baseline GFR,
smoking, and diabetes
Gelber et al.29 USA 11 104, X40
(men)
14 Q1 BMIo22.7b
Q2 (22.7–23.7)
Q3 (23.8–25.0)
Q4 (25.1–26.6)
Q5 BMI426.6
Continuous BMI
R CKD OR:
1.13 (0.92–1.38) for Q2
1.15 (0.94–1.41) for Q3
1.32 (1.09–1.61) for Q4
1.26 (1.03–1.54) for Q5
1.03 (1.01–1.05)
(1) Higher BMI increased risk
of CKD
(2) Subjects were white male
professionals
(3) Confounders adjusted for
age, smoking, alcohol use,
exercise, diabetes mellitus,
hypertension, and
cardiovascular disease
Iseki et al.30 Japan 100 753, X20 17 Q1: BMIo21.0b
Q2: 21.0–23.1
Q3: 23.2–25.4
Q4: BMIX25.5
M ESRD OR: total
1.48 (1.07–2.06) for Q2
1.34 (0.96–1.86) for Q3
1.48 (1.08–2.03) for Q4
Men:
1.79 (1.12–2.85) for Q2
1.95 (1.23–3.09) for Q3
2.39 (1.53–3.74) for Q4
Women:
1.25 (0.78–1.99) for Q2
0.88 (0.54–1.45) for Q3
0.96 (0.60–1.51) for Q4
(1) Higher BMI increased risk
of ESRD in men, but not in
women
(2) Confounders adjusted for
age, systolic blood pressure,
and proteinuria
Hsu et al.6 USA 320 252, X18 15–35 Underweight:
BMIo18.5
Normal weight
BMI: 18.5–24.9b
Overweight:
BMI 25–29.9
Obesity
Class I: 30–34.9
Class II: 35–39.9
Class III: BMIX40
M ESRD Total
0.44 (0.15–1.00) for underweight
1.87 (1.64–2.14) for overweight
3.57 (3.05–4.18) for obesity
class I
6.12 (4.97–7.54) for obesity
class II
7.07 (5.37–9.31) for obesity
class III
Men:
0.2 (0.0–1.4) for underweight
1.8 (1.5–2.1) for overweight
3.6 (2.9–4.4) for obesity class I
7.3 (5.4–9.9) for obesity class II
9.4 (6.0–14.7) for obesity class III
Women:
0.6 (0.3–1.2) for underweight
2.2 (1.7–2.7) for overweight
3.6 (2.8–4.6) for obesity class I
5.4 (4.1–7.3) for obesity class II
6.5 (4.6–9.3) for obesity class III
(1) Higher BMI increased risk
of ESRD
(2) Confounders adjusted
for gender, age, ethnicity,
smoking education, serum
of cholesterol level, history
of myocardial infarction,
proteinuria, hematuria, and
serum of creatinine level
Taylor et al.31 USA (1) HPFS 51
529, 40–75
(men)
(2) NHS I 121
700, 30–55
(women)
(3) NHS II
101 877, 25–42
(women)
16
20
10
L1: BMIo21
L2: 21–22.9b
L3: 23–24.9
L4: 25–27.4
L5: 27.5–29.9
L6: BMIX30
R Kidney
stone
(1) HPFS (men):
0.73 (0.52–1.03) for L1
0.94 (0.79–1.12) for L3
1.20 (1.02–1.41) for L4
1.24 (1.03–1.50) for L5
1.33 (1.08–1.63) for L6
(2) NHS I (women):
1.15 (0.95–1.38) for L1
1.26 (1.07–1.50) for L3
1.34 (1.13–1.59) for L4
1.75 (1.45–2.10) for L5
1.90 (1.61–2.25) for L6
(3) NHS II (women):
1.13 (0.94–1.36) for L1
1.24 (1.04–1.50) for L3
1.47 (1.22–1.77) for L4
1.68 (1.36–2.07) for L5
2.09 (1.77–2.48) for L6
(1) Obesity increased risk of
kidney stone formation
(2) The association was
stronger in women than in
men
(3) Subjects were
predominately white
(4) Confounders adjusted for
age, alcohol use, calcium
supplement use, dietary
intake of fluid, animal
protein, calcium, magnesium,
potassium, sodium, and
vitamin C
Rapp et al.32 Austria
(VHM&PP)
145 931 (men,
67 447; women,
10 BMI 18.5–24.9b
Overweight:
M Kidney
cancer
Men:
1.19 (0.82–1.74) for overweight
1.46 (0.87–2.46) for obesity
(1) Overweight increased risk
of kidney cancer in women,
but not in men
Table 1 continued on following page
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Table 1 | Continued
Reference Country
N, age
(years)
Follow-up
(years)
Exposure assessment:
obesity/overweight
(BMI: kg m2)
BMI
M/Ra Outcome
Main findings: RR
(or OR) and 95% CI Comments
78 484)
19–94
BMI 25–29.9
Obesity: BMIX30
Women:
1.81 (1.13–2.89) for overweight
1.14 (0.58–2.24) for obesity
(2) Subjects being
underweight (BMIo18.5) and
having kidney cancer before
or within 1-year following
enrolment excluded
(3) Confounders adjusted for
age, gender, smoking, and
occupation
Calle et al.20 USA 900 053 (men,
404 576; women,
495 477), X30
16 Normal weight
BMI: 18.5–24.9b
Overweight:
BMI 25–29.9
Obesity
Class I: 30–34.9
Class II: 35–39.9
Class III: BMIX40
R Kidney
cancer
Men:
1.18 (1.02–1.37) for overweight
1.36 (1.06–1.74) for obesity
class I
1.70 (0.99–2.92) for obesity
class II
No data reported for obesity
class III
Women:
1.33 (1.08–1.63) for overweight
1.66 (1.23–2.24) for obesity
class I
1.70 (0.94–3.05) for obesity
class II
4.75 (2.50–9.04) for obesity
class III
(1) Higher BMI increased risk
of kidney cancer, especially in
women
(2) Subjects with
underweight (BMIo18.5) and
with kidney cancer excluded
at baseline
(3) Confounders adjusted for
age, ethnicity, smoking,
education, exercise, alcohol
use, marital status, aspirin
use, fat consumption,
vegetable consumption, and
HRT use in women
Nicodemus
et al.33
USA (IWHS) 34 637 (women)
55–69
15 Q1: BMIo22.9b
Q2: 22.9–25.0
Q3: 25.0–27.4
Q4: 27.4–30.6
Q5: BMI430.6
R Kidney
cancer
0.80 (0.38–1.65) for Q2
1.46 (0.77–2.74) for Q3
1.87 (1.02–3.41) for Q4
2.49 (1.39–4.44) for Q5
(1) Higher BMI increased risk
of kidney cancer
(2) Confounders adjusted for
age
Pischon et al.34 European
countries (EPIC:
Germany,
Denmark, Greece,
Italy, UK, the
Netherlands,
Sweden, and
Spain)
348 550, 25–70 6 Normal: BMIo25b
Overweight:25–30
Obesity: BMIX30
M RCC Men:
0.81 (0.55–1.20) for overweight
1.06 (0.60–1.75) for obesity
Women:
1.40 (0.96–2.25) for overweight
1.68 (1.03–2.75) for obesity
(1) Significant association in
women, but not in men
(2) Confounders adjusted for
age, smoking, education,
alcohol, and exercise
(menopausal status and HRT
use also adjusted in women)
Oh et al.35 Korea (KNHIC) 781 283, X20
(men)
10 BMIo18.5
BMI: 18.5–22.9b
BMI: 23.0–24.9
BMI: 25.0–26.9
BMI: 27.0–29.9
BMIX30
M RCC 0.29 (0.07–1.17) for BMIo18.5
1.06 (0.84–1.34) for BMI 23.0–24.9
1.23 (0.94–1.61) for BMI 25.0–26.9
1.89 (1.37–2.60) for BMI 27.0–29.9
1.62 (0.66–3.94) for BMIX30
(1) Higher BMI increased risk
of RCC
(2) Confounders adjusted for
age, smoking, alcohol use,
exercise, residence, and
family history of cancer
Bjorge et al.36 Norway 2 001 719,
20–74
23 Underweight:
BMIo18.5
Normal weight
BMI: 18.5–24.9b
Overweight:
BMI 25–29.9
Obesity: BMIX30
M RCC Men:
0.44 (0.22–0.88) for underweight
1.18 (1.11–1.26) for overweight
1.55 (1.36–1.76) for obesity
Women:
0.88 (0.60–1.30) for underweight
1.32 (1.21–1.45) for overweight
1.85 (1.66–2.06) for obesity
(1) Significant association in
both men and women
(2) Confounders adjusted for
age and height
Chow et al.37 Sweden 363 992, 44 (men) 16 L1: BMIp20.75b
L2: 20.76–21.9
L3: 21.91–22.85
L4: 22.86–23.80
L5: 23.81–24.76
L6: 24.77–25.95
L7: 25.96–27.75
L8: BMIX27.76
M RCC 1.2 (0.7–1.8) for Q2
0.9 (0.6–1.5) for Q3
1.4 (0.9–2.1) for Q4
1.6 (1.1–2.4) for Q5
1.3 (0.8–1.9) for Q6
1.7 (1.1–2.5) for Q7
1.9 (1.3–2.7) for Q8
(1) Higher BMI increased risk
of RCC
(2) Confounders adjusted for
age, smoking, and blood
pressure
Health et al.38 USA 998 904, X30 7 Men
Q1: BMIo20.7
Q2: 20.7–24.6b
Q3: 24.7–27.7
Q4: 27.8–31.0
Q5: BMIX31.1
Women
Q1: BMIo19.1
Q2: 19.1–21.9b
Q3: 22.0–27.2
Q4: 27.3–32.2
Q5: BMIX32.3
R RCC Men:
0.6 (0.2–1.5) for Q1
1.1 (0.8–1.6) for Q3
1.6 (1.1–2.3) for Q4
1.6 (0.9–2.7) for Q5
Women:
0.6 (0.1–2.5) for Q1
1.5 (0.9–2.6) for Q3
2.5 (1.4–4.4) for Q4
3.1 (1.5–6.4) for Q5
(1) Significant association in
men and women
(2) The association was
stronger in women than in
men
(3) Confounders adjusted for
age, smoking, hypertension,
history of urologic disease,
and family history of kidney
cancer
Flaherty et al.39 USA (1) HPFS 48 953,
40–75 (men)
(2) NHS 118 191,
30–55 (women)
12
24
Q1: BMIo22.0b
Q2: 22.0–24.9
Q3: 25.0–27.9
Q4: 28.0–29.9
Q5: BMIX30.0
R RCC (1) HPFS (men):
2.1 (0.7–5.9) for Q2
2.4 (0.9–6.8) for Q3
2.1 (0.7–6.6) for Q4
2.1 (0.7–6.8) for Q5
(1) Higher BMI increased risk
of RCC in women but not in
men
(2) Subjects were
predominately white
Table 1 continued on following page
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Table 1 | Continued
Reference Country
N, age
(years)
Follow-up
(years)
Exposure assessment:
obesity/overweight
(BMI: kg m2)
BMI
M/Ra Outcome
Main findings: RR
(or OR) and 95% CI Comments
(2) NHS (women):
1.3 (0.9–2.0) for Q2
1.6 (0.9–2.5) for Q3
2.2 (1.2–4.1) for Q4
No data reported for Q5
(3) Confounders adjusted for
age, hypertension, and
smoking status
Tozawa et al.40 Japan 5403, 4879 3 Obesity: BMIX25 M Proteinuria All: 1.45 (1.13–1.86)
Men: 1.60 (1.19–2.14)
Women: 1.04 (0.63–1.72)
(1) Significant association in
men, not in women
(2) Confounders adjusted for
age, gender, exercise,
smoking, alcohol, diabetes
mellitus, anemia, and
hypertension
BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; EPIC, the European Prospective Investigation into Cancer and Nutrition; ESRD, end-stage renal
disease; FOS, Framingham Offspring Study; GFR, glomerular filtration rate; HPFS, Health Professionals Follow-up Study; HRT, hormone replacement therapy; IWHS, Iowa
Women’s Health Study; KNHIC, Korea National Health Insurance Corporation; NHANES, National Health and Nutrition Examination Surveys; NHS, Nurses’ Health Study; OR,
odds ratio; RCC, renal cell carcinoma; RR, relative risk; VHM&PP, the Vorarlberg Health Monitoring and Promotion Program.
aM, BMI directly measured; R, BMI self-reported.
bReference group.
Table 2 | Characteristics and main findings of six included cohort studies on the association between obesity and kidney
disease in patient populations, by outcome and country of data collection
Reference Country Subjects
N, age
(years)
Follow-up
(years)
Exposure assessment
(BMI: kg m2)
BMI
M/Ra Outcome
Main finding: RR
(or OR) and 95% CI Comments
Kramer
et al.41
USA Patients with
hypertension
5897, 51710 5 Normal weight:
18.5–24.9b
Overweight: 25–29.9
Obesity: BMIX30
M CKD OR: 1.22 (1.05–1.43) for
overweight
1.38 (1.17–1.63) for obesity
(1) Overweight and
obesity increased risk
of CKD
(2) Confounders adjusted
for age, gender,
ethnicity, diabetes
mellitus, and blood
pressure
Perry
et al.42
USA Patients with
hypertension
(men)
11 912, 53710 15 BMI category
Q1: BMIp24b
Q2: 24.1–26
Q3: 26.1–30
Q4: BMI430
R ESRD Univariate analysis
0.94 (0.63–1.42) for Q2
0.58 (0.40–0.86) for Q3
0.92 (0.63–1.35) for Q4
No data in multivariate
analysis reported
No association was
observed between BMI
and risk of ESRD
Bonnet
et al.43
France Patients with IgA
nephropathy
162, 44713 8 Normal weight:
BMIo25b
Overweight:
BMIX25–29.9
Obesity: BMIX30
R CRF 1.1 (1.0–1.2) for BMI at the
time of first renal biopsy
2.1 (0.9–4.7) for overweight
(1) BMI at the time of first
renal biopsy increased
risk of CRF
(2) Confounders adjusted
for age, hypertension,
sex, and
hypertriglyceridemia
Ducloux
et al.44
France Patients with RT 292, 45713 1 1 year after RT BMI
increase p5% vs
45%
M Graft loss 2.82 (1.11–7.44) (death
censored)
2.31 (1.06–5.04) (death
uncensored)
(1) Post-RT weight gain
increased risk of graft
loss
(2) Confounders adjusted
for age, gender,
hypertension, diabetes,
and low HDL level
Meier-Kriesche
et al.45
USA Patients with RT 51 927, 418 11 BMIo18,
BMI 18–20
BMI 20–22
BMI 22–24
BMI 24–26b
BMI 26–28
BMI 28–30
BMI 30–32
BMI 32–34
BMI 34–36
BMI436
M Graft loss 1.21 (1.11–1.32) for BMIo18
1.11 (1.04–1.19) for 18–20
1.03 (0.98–1.09) for 20–22
0.96 (0.91–1.02) for 22–24
1.07 (1.01–1.14) for 26–28
1.07 (1.00–1.14) for 28–30
1.18 (1.10–1.27) for 30–32
1.15 (1.06–1.26) for 32–34
1.21 (1.08–1.34) for 34–36
1.39 (1.3–1.55) for BMI436
(1) A U-shaped
association between pre-
transplantation BMI and
risk for graft loss
(2) Confounders adjusted
for age, ethnicity,
gender, primary cause of
ESRD, donor source, and
other treatment modality
Massarweh
et al.46
USA Patients with RT 193, 4771 12 Non-obesity:
BMIo30.0b
Obesity: BMIX30.0
M Graft loss OR: 0.93 (0.50–1.72) (1) No association
(2) Confounders adjusted
for age, gender, donor
source, diabetes, HLA
mismatch, and donor
race
BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; CRF, chronic renal failure; ESRD, end-stage renal disease; HDL, high-density lipoprotein;
HLA, human leukocyte antigen; IgA, immunoglobulin A; OR, odds ratio; RR, relative risk; RT, renal transplantation.
aM, BMI directly measured; R, BMI self-reported.
bReference group.
Kidney International (2008) 73, 19–33 23
Y Wang et al.: Obesity and kidney disease r e v i e w
1.94 (1.49–2.52), respectively. Another study of 7676 non-
diabetic subjects found that elevated waist–hip ratio increased
the risk for diminished glomerular filtration rate (GFR), even
after controlling for BMI.69
The association between obesity and KD: meta-analysis of
cohort studies in the general population
Figure 1 shows the RRs and 95% confidence interval (95%
CIs) from each individual study and the random-effects
pooled estimates. Our estimated pooled RRs clearly show
that overweight and obesity increased the risk of KD.
Compared with normal-weight individuals, overweight and
obese persons had significantly higher risk of KD (Table 3).
The pooled RRs were 1.40 (1.30–1.50) for overweight and
1.83 (1.57–2.13) for obesity; and the P-value of between-study
heterogeneity was o0.01 and o0.001, respectively.
Next, we tested the differences by gender, type of KD, and
method of ascertaining BMI. The association between obesity
and KD was stronger in women than in men, odds ratio
(OR)¼ 1.92 (1.78–2.07) vs 1.49 (1.36–1.63) (Po0.001).
Regarding cancers of the kidney (including RCC), the pooled
RR was 1.87 (1.69–2.07) for obese women vs 1.53 (1.38–1.69)
for obese men (Po0.01). When kidney cancer was excluded,
the gender difference becomes greater, the pooled RRs being
1.99 (1.77–2.24) vs 1.33 (1.08–1.63) (Po0.01). The RRs for
self-reported BMI were higher than those for directly
measured BMI, that is the effect might be inflated due to
reporting bias, but the difference was not significant
(P40.05). Finally, we treated BMI as a continuous variable.
For each 1 kg m2 unit increase in BMI, the pooled RR of KD
was 1.06 (1.05–1.07) (Po0.001).
Assessment of publication bias. We assessed possible
publication bias using a Begg’s funnel plot (Figure 2). For
overweight (Figure 2a), the plot revealed slightly more data
points above the horizontal line (representing the pooled
estimate of Log(RR)), which indicates a possible minor
publication bias. However, neither Begg’s adjusted rank
correlation test nor Egger’s regression asymmetry test was
significant (P40.05). The results were similar for obesity
(Figure 2b).
Overweight (25≤BMI<30) vs normal weight
Obesity (BMI≥30) vs normal weight
Stengel (2003)
Stengel (2003)
CKD
Abbreviation
CKD: chronic kidney disease
ESRD: end-stage renal disease
KS: kidney stone
KC: kidney cancer
RCC: renal cell carcinoma
CKD
CKD
ESRD
ESRD
ESRD
KS
KS
KS
KS
KS
KS
KC
KC
KC
KC
RCC
RCC
RCC
RCC
RCC
RCC
RCC
RCC
RCC
RCC
RCC
RCC
RCC
RCC
RCC
RCC
Gelber (2005)
Iseki (2004)
Hsu (2006)
Hsu (2006)
Taylor (2005)
Taylor (2005)
Taylor (2005)
Taylor (2005)
Taylor (2005)
Taylor (2005)
Calle (2003)
Calle (2003)
Rapp (2005)
Rapp (2005)
Pischon (2006)
Pischon (2006)
Oh (2005)
Oh (2005)
Bjorge (2004)
Bjorge (2004)
Chow (2000)
Chow (2000)
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Nicodemus (2004)
Nicodemus (2004)
Flaherty (2005)
Flaherty (2005)
Flaherty (2005)
Tozawa (2002)
Pooled RR
Pooled RR
0.5
0.5
Test for heterogeneity: Q=37.11, P=0.003; Pooled RR (95% Cl): 1.40 (1.30–1.50).
Test for heterogeneity: Q=40.96, P=0.001; Pooled RR (95% Cl): 1.83 (1.57–2.13).
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1.5
1
1
2
2
RR (95% cl)
RR (95% cl)
5
5
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Figure 1 | Pooled random-effects estimate of RR and 95% CI for the association between obesity and KD based on cohort studies
in the general populations. (a) Overweight (25pBMIo30) vs normal weight. Test for heterogeneity: Q¼ 37.11, P¼ 0.003; pooled RR
(95% CI): 1.40 (1.30–1.50). (b) Obesity (BMIX30) vs normal weight. Test for heterogeneity: Q¼ 40.96, Po0.001; pooled RR (95% CI): 1.83 (1.57–2.13).
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Population attributable risk. We calculated population
attributable risk (PAR) of overweight and obesity for
KD based on the current prevalence in the United States70
and in industrialized countries.71 Approximately one-fourth
(24.2%) of KD cases among American men and over one-
third (33.9%) among American women could be prevented if
overweight and obesity (BMIX25 kg m2) were eliminated
(Table 4). In industrialized countries, overweight and obesity
Table 3 | Pooled RR and 95% CI of KD in 18 general population cohort studies according to BMI categoriesa
BMI categories
Number of cohorts
Underweight
(BMIo18.5)
Normal
(18.5pBMIo25)
Overweight
(25pBMIo30)
Obesity
(BMIX30)
All studies 18 0.92 (0.74–1.15) 1 (ref) 1.40 (1.30–1.50) 1.83 (1.57–2.13)
Gender difference
All studies
Men 11 0.63 (0.48–0.85) 1 (ref) 1.31 (1.18–1.45) 1.49 (1.36–1.63)b***
Women 11 1.11 (0.98–1.25) 1 (ref) 1.41 (1.32–1.50) 1.92 (1.78–2.07)
KD excluding kidney
cancer/RCC
Men 3 0.73 (0.52–1.03) 1 (ref) 1.59 (1.12–2.26) 1.33 (1.08–1.63)b**
Women 4 1.14 (1.00–1.30) 1 (ref) 1.48 (1.32–1.66) 1.99 (1.77–2.24)
Kidney cancer/RCC
Men 8 0.45 (0.27–0.77) 1 (ref) 1.21 (1.15–1.27)b** 1.53 (1.38–1.69)b**
Women 7 0.86 (0.59–1.26) 1 (ref) 1.38 (1.28–1.49) 1.87 (1.69–2.07)
BMI assessment
Directly measured 9 0.76 (0.56–1.04) 1 (ref) 1.38 (1.22–1.56) 1.78 (1.33–2.40)
Self-reported 9 1.07 (0.94–1.20) 1 (ref) 1.39 (1.27–1.53) 1.84 (1.56–2.17)
Specific KD outcomes
KD excluding kidney 1 (ref)
Cancer/RCC 8 1.08 (0.96–1.22) 1.42 (1.27–1.60) 1.95 (1.45–2.64)
CKD 3 1.30 (0.52–3.24) 1 (ref) 1.26 (1.10–1.45) 1.34 (0.86–2.09)
ESRD 2 NRc 1 (ref) 1.68 (1.49–1.90) 4.07 (2.87–5.76)
Kidney stone 3 1.08 (0.95–1.22) 1 (ref) 1.41 (1.18–1.69) 1.75 (1.36–2.25)
Kidney cancer/RCC 10 0.70 (0.51–0.95) 1 (ref) 1.31 (1.23–1.40) 1.71 (1.53–1.93)
BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; ESRD, end-stage renal disease; KD, kidney disease; RR, relative risk; RCC, renal cell carcinoma.
aData from one study5 shown in Table 1 are excluded in this table.
bGender difference, **Po0.01; ***Po0.001.
cNR, No results were reported for underweight.
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* Horizontal lines indicate the random effects pooled estimates of RRs and 95% CIs; sloping lines
represent the expected 95% CIs for a given SE, assuming heterogeneity between studies. Neither the Begg’s
adjusted-rank correlation tests nor the Egger’s regression asymmetry test is significant for overweight or
obesity, P=0.21 and 0.32 for overweight; and P=0.96 and 0.88 for obesity, respectively.
Figure 2 | Funnel plot regarding RR on a log scale on its standard error for the 18 separated cohorts included in the meta-analysis.
(a) Overweight (25pBMIo30) vs normal weight. (b) Obesity (BMIX30) vs normal weight. Horizontal lines indicate the random-effects pooled
estimates of RRs and 95% CIs; sloping lines represent the expected 95% CIs for a given standard error, assuming heterogeneity between
studies. Neither the Begg’s adjusted rank correlation tests nor the Egger’s regression asymmetry test is significant for overweight or obesity,
P¼ 0.21 and 0.32 for overweight and P¼ 0.96 and 0.88 for obesity, respectively.
Kidney International (2008) 73, 19–33 25
Y Wang et al.: Obesity and kidney disease r e v i e w
together accounted for 24.0% of KD cases, 16.5% in men and
26.3% in women. For kidney cancer (including RCC), the
corresponding PARs were 21.8% in American men and
32.2% in American women; and in industrialized countries,
13.8% in men and 24.9% in women.
DISCUSSION
The growing worldwide obesity epidemic affects both
industrialized and developing countries and is likely to have
far-reaching health and social consequences. A growing
number of studies have examined the association between
obesity and KD, suggesting that obesity increases the risk of
KD as well as its progression among diagnosed KD patients.
Our meta-analysis, based on prospective cohort studies in
different populations, provides strong evidence to help
quantify the impact of obesity on KD. Compared with
normal-weight individuals, overweight persons have a 40%
higher risk for KD (pooled RR¼ 1.40 (1.30–1.50)), and obese
persons exhibit even higher risk (RR¼ 1.83) (1.57–2.13)).
Most reviewed studies adjusted for potential confounders,
such as age, gender, ethnicity, smoking status, alcohol use,
and physical activity. Some studies also adjusted for diabetes
mellitus, dyslipidemia, and hypertension. It seems that at
least part of the impact of obesity on KD risk is independent
of these major risk factors.
The majority of the cohort studies we examined indicate a
dose–response relationship between BMI and KD risk, while
some suggest a J-shaped association. For example, a large 21-
year follow-up study followed 320 252 adults and reported a
linear dose–response association between BMI and the risk
for ESRD.6 The Framingham Offspring Study suggests that
baseline BMI predicts subsequent KD after a mean follow-up
of 18.5 years.5 In this community-based cohort of 2585 men
and women, each unit increase in BMI was associated with a
1.23-fold increased risk for new-onset KD. In general, higher
BMIs, especially obesity, were associated with an increased
risk of KD. On the other hand, several studies show that very
low BMI is also associated with an increased risk of KD. But
our meta-analysis demonstrates that the association between
underweight and KD is not significant, except for kidney
cancer (RR¼ 0.70; 95% CI 0.51–0.95), which indicates a
reduced risk and it is different from what we have expected.
Gender differences
Our analyses suggest some gender differences in the relation-
ship between obesity and the risk of KD. Compared with
their normal-weight counterparts, obese women were at
higher risk for KD than obese men. In contrast, a previous
meta-analysis found no evidence of gender difference in the
association between obesity and RCC based on 24 studies
published before 1998.26 Most of the included studies in the
previous meta-analysis were case–control studies (17/24).
Their reported pooled RR for each unit increase in BMI was
1.07 (1.04–1.09) in men vs 1.07 (1.05–1.09) in women. Of
note, a recent large 17-year cohort study (n¼ 100 753)
conducted in Japan found a strong dose–response relation-
ship between BMI and risk of ESRD in men, but no
association in women.30
The explanation for the apparent gender difference we
detected remains unclear. It is speculated that the differences
in exposure to hormones (especially estrogen), body
composition, or dietary factors may contribute to the gender
difference, at least regarding the risk of RCC. Since women
generally have a higher percent body fat than men, women
have more adipose tissue than men with the same BMI.
Taylor et al.31 argued that the gender difference observed in
the relationship between BMI and risk of KD could have
more to do with estimation of adiposity than with any
fundamental difference in physiology. Further studies are
needed to clarify these differences, which seem to vary by KD
outcome and study population.
Differences in results based on measured and reported BMI
Some studies used self-reported weight and height. Although
in general such data have been shown to be highly correlated
with the actual measurements, obese subjects tend to under-
report their weight, while underweight subjects tend to
overestimate their body size, with an overestimation of
height.72–74 Thus, self-reported BMI is more likely to
underestimate the true BMI values among subjects with
overweight and obesity than among individuals with normal
weight.20 This might lead to non-differential misclassifica-
tion, which might have inflated the RR. Our findings do
suggest the pooled RRs based on reported BMI were slightly
greater than those based on measured BMI, 1.84 (1.56–2.17)
vs 1.78 (1.33–2.40) for obesity; however, the difference was
Table 4 | PAR of KD due to overweight and obesity in the
United States and industrialized countriesa
USAb Industrialized countriesc
All Men Women All Men Women
Prevalence (%)
Overweight 34.1 39.7 28.6 33.6 38.1 29.3
Obesity 32.2 31.1 33.2 16.6 12.9 20.1
PAR (%) of overall KD
Overweight 12.0 11.0 10.5 11.8 10.6 10.7
Obesity 21.1 13.2 23.4 12.1 5.9 15.6
Total 33.1 24.2 33.9 24.0 16.5 26.3
PAR (%) of non-kidney cancer/RCC
Overweight 12.5 19.0 12.1 12.4 18.4 12.3
Obesity 23.4 9.3 24.7 13.6 4.1 16.6
Total 36.0 28.3 36.8 26.0 22.4 28.9
PAR (%) of kidney cancer/RCC
Overweight 9.6 7.7 9.8 9.4 7.4 10.0
Obesity 18.6 14.2 22.4 10.5 6.4 14.9
Total 28.2 21.8 32.2 20.0 13.8 24.9
IOTF, International Obesity Task Force; KD, kidney disease; NHANES, National Health
and Nutrition Examination Surveys; PAR, population attributable risk; RCC, renal cell
carcinoma.
aRRs were based on our meta-analysis (see Table 3).
bPrevalence estimates were based on NHANES 2003–2004 data.26
cPrevalence estimates were based on IOTF’s estimates.
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small and not statistically significant. In addition, the
difference may also be due to the fact that these studies
examined different KD outcomes. Validation studies in
cohorts of health professionals have demonstrated the
reliability of self-reported height and weight.75 Our findings
further support that in large epidemiological studies, results
based on measured or self-reported BMI are comparable.
Body fat distribution
Only a limited number of cohort studies have compared the
association between overall obesity and risk of KD with that
of central obesity. While some studies found significant
increases in risk attributable to central obesity, among
women, waist and hip circumference were no longer
significant after controlling for body weight.34 This suggests
that general adiposity is a more important determinant of
risk in women. Among men, hip circumference was inversely
related to RCC risk even after accounting for body weight,
suggesting that fat distribution pattern may be more
predictive of RCC risk than overall obesity in men.34 This
may reflect a substitution effect, with more subcutaneous
peripheral and less visceral abdominal fat. Overall, it appears
that central obesity seems to be important for renal
impairment, at least in men, although further research is
needed.
Population attributable risk
We estimated the population attributable risk for excess
weight based on the current prevalence of overweight and
obesity in the United States and industrialized countries. We
estimated that over one-fourth (24.2% in men vs 33.9% in
women) of KD cases in the United States and one-fifth in
industrialized countries (16.5 vs 26.3%) could be prevented
by eliminating overweight and obesity. Previously, Bergstrom
et al.26 estimated that approximately 30% of RCC cases (27%
in men and 29% in women) could be related to overweight
and obesity in the United States. Our study found that fewer
(24%, 16.5% in men and 26.3% in women) of kidney cancer
(including RCC) cases were attributable to overweight and
obesity. Our estimates are likely to be more accurate because
of more selective study inclusion criteria and the inclusion of
recently published studies.
Biological mechanisms for the effects of obesity on KD
The current understanding of the biological mechanisms for
the effects of obesity on KD remains limited. Obesity may
promote kidney damage directly through hemodynamic and
hormonal effects27,76 or indirectly by favoring the develop-
ment of diabetes and hypertension, and disorders with strong
kidney involvement. Some data suggest that obesity and
diabetes may have similar effects on the kidney.77 In the
initial stages of kidney dysfunction due to diabetes,
GFR tends to increase, due to increased glomerular
capillary pressure, a process called glomerular hyperfiltra-
tion. This may be followed by increased urinary albumin
excretion (microalbuminuria when the rate of loss reaches
30–300 mg per 24 h). The microalbuminuria phase
is followed by a progressive fall in GFR, in parallel
with a further rise in urinary albumin, then overt proteinuria
and, eventually, ESRD.27 In general, studies included in
our meta-analysis estimated GFR using the abbreviated equa-
tion from the Modification of Diet in Renal Disease Study
and defined CKD/ESRD as GFRo60 ml min1 1.73 m2
(o1 ml s1 1.73 m2)29 or the GFR less than the 5th
percentile (e.g., p59.25 ml min1 1.73 m2 in women and
p64.25 ml min1 1.73 m2 in men).5 The pathogenic me-
chanism responsible for microalbuminuria/proteinuria in
obese subjects is speculated to be glomerular hyperfiltra-
tion.78 Both animal and human studies have demonstrated
that obesity leads to glomerular hyperperfusion and hyperfil-
tration, which, in turn, causes proteinuria and focal
segmental glomerulosclerosis.76,79 Pathologic evidence ob-
tained from kidney biopsy specimens has documented the
emergence of obesity-related glomerulopathy. In addition,
leptin secreted from excess adipose tissue might directly lead
to renal fibrosis.79
It is worth noting that a possible limitation of some
previous studies is related to their assumption that the
hydration of lean body mass and adipose is normal and has
not changed within the initial years of KD, in particular,
those studies conducted among KD patients. The abnormal
hydration of lean body mass and adipose as well as fat
distribution patterns especially at late stage of KD patients
might have affected their findings of the association between
obesity and KD. Results of prospective cohort studies among
KD patients (e.g., immunoglobulin A nephropathy) show
that, in general, patients who were overweight or obese at
baseline had worse outcomes than their normal-weight
counterparts during follow-up. It is possible that part of
their elevated weight might be due to edema at a later stage of
KD. The findings of cohort studies conducted in the general
populations provide good evidence regarding the causality
between obesity at baseline and later risk for KD, as
overweight of these non-KD patients is unlikely due to
edema.
It is possible that the exact mechanisms responsible for the
association between obesity and KD may vary for different
forms of KD. For example, in contrast to the GFR-related
pathogenesis of chronic KD, hypothesized reasons for the
association between obesity and RCC include increased levels
of estrogens and insulin associated with obesity, a higher
concentration of growth factors in the excess adipose tissue,
an abnormality in the metabolism of cholesterol, as well as
alterations in the immune system.80 In our meta-analysis, we
aimed to examine the overall influence of obesity on KD,
including that through its influence on conditions such as
type II diabetes and hypertension. Some cohort studies that
controlled for these conditions still found a positive
association between obesity and KD. Thus, obesity may
affect the risk of KD, independent of type II diabetes or
hypertension, although it is likely that at least part of its effect
might be due to its influence on the latter.
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Our meta-analysis allowed us to combine prospective
evidence across available studies by reducing random
sampling error and increasing statistical power. Certainly,
there are several limitations that merit consideration. First,
our analyses of observational studies, and the inherent
limitations of such studies may affect our findings. The
possibility of residual confounding or bias including
measurement errors cannot be excluded. Second, differences
in study population, assessment of covariates and exposure
variables, classification and validation of KD end points,
coupled with the possibility that many of the studies
under investigation had a varying total of follow-up
years, all may contribute to heterogeneity across studies
and thus affect the pooled estimates. Nevertheless, the
bias from individual studies usually tends to be relatively
small and does not substantially influence the overall
estimates in a meta-analysis, as more studies are included.
In addition, our subgroup analyses did not support the
presence of potential effect modification by these factors.
Finally, the possibility of publication bias is always a concern
in the meta-analysis. Since the observed associations were
remarkably consistent across most of the cohort studies, the
likelihood that these findings are solely due to selective
publication seems unlikely.
Future research in this area should focus on the
mechanisms for the increased risk for KD and for KD
progression; causes of the gender- and inter-population
differences in the association; the interaction between excess
adiposity and response to therapy in kidney patients; the
impact of weight loss on kidney function, disease progres-
sion, and survival; and the development of effective obesity
prevention and weight management approaches for patients
with KD or at risk of KD.
In conclusion, our meta-analysis shows a clear association
between obesity and KD based on data collected from a large
number of research subjects in diverse populations. Obesity is
a strong and potentially modifiable risk factor for the
development and progression of KD. Thus, efforts to prevent
and treat obesity can be expected to have a major impact on
the incidence, progression of KD of various kinds, and its
substantial costs and comorbidities.
MATERIALS AND METHODS
Literature search strategy
PubMed (www.ncbi.nlm.nih.gov/entrez) was searched for studies
published from 1 January 1980 to 30 April 2006. Several key words
were incorporated into our search, including overweight, obesity,
BMI, central obesity, KD, renal disease, renal disorder, and kidney
cancer. Titles and abstracts of studies uncovered by the electronic
searches were examined on screen first. Only studies that examined
the associations between obesity (including overweight and BMI)
and KD in adults and published in English between January 1980
and April 2006 were included. This search resulted in a total of 247
studies in the first round of screening, which were then examined for
exclusion and inclusion criteria. In addition, some studies identified
in the course of reading or brought to our attention by colleagues
and experts consulted were included.
Study inclusion and exclusion criteria
Studies were included if they met the following criteria: (1) having a
measure of RR or OR and the 95% CI, (2) enrolling adults aged 18
years and above, (3) having a sample size of greater than 100, (4)
having a measure of body weight (overweight or obesity) using BMI
or measures that could be converted to BMI, (5) presenting
sufficient detailed results, and (6) it consisted only cohort, cross-
sectional, or case–control studies, but not other types of studies such
as case reports. In addition, when multiple studies had been
published based on the same cohort, only the most recent one, with
the longest follow-up period, was included. A total of 44 eligible
studies (25 cohort, 3 cross-sectional, and 19 case–control studies)
were included in this study.
We chose to restrict our meta-analysis to the 18 cohort studies
conducted in the general population for the following reasons: (a)
they provided reliable evidence regarding the causality between
obesity and KD, and (b) the number of other types of studies was
relatively small and did not allow for meaningful analysis. Using our
estimated pooled RRs, we calculated PAR. Note that other study
designs other than prospective cohort studies do not imply
causality; and PAR is meaningful only when population-based
prevalence and risk estimates are used.
In addition, we examined whether body fat distribution affected
the risk of KD in studies that provided information both on overall
obesity assessed using BMI and central obesity assessed using WC or
waist–hip ratio. An additional nine studies that met our criteria were
identified and described.
Assessment of body weight and classification of obesity and
overweight
Varying BMI cutoff points were used to classify underweight,
normal weight, overweight, and obesity in these studies. Some used
BMI quartiles or quintiles, though most followed the World Health
Organization’s (WHO) recommended BMI cutoff points: (a)
underweight, o18.5 kg m2; (b) normal weight, 18.5–24.9 kg m2;
(c) overweight, 25–29.9 kg m2; (d) obesity, BMX30 kg m2; and/or
(e) class I obesity, 30–34.9 kg m2; class II obesity, 35–39.9 kg m2;
class III obesity, X40 kg m2.1 Most of our included studies
were based on directly measured weight and height, while some
used self-reports.
Classification and diagnosis of KD
In most of the studies reviewed, KD was defined according to the
International Classification of Disease,81 and was diagnosed based
on medical records, death certificates, and/or autopsy reports. This
study included the following KD-related outcomes: CKD, CRF,
ESRD, kidney stones, and kidney cancer/RCC.
Data extraction
Using a standardized data extraction form, two investigators (XC
and YW) extracted and tabulated all data, and discrepancies were
resolved by group discussions. Information extracted included lead
author, year of publication, country of data collection, sample
characteristics (e.g., age, gender, sample size), study design, length of
follow-up for cohort studies, assessment of body weight status (i.e.,
measured vs self-report, BMI cut points used), classification of KD,
reported RRs or ORs, and 95% CIs from which variances were
derived. In addition, we added comments regarding the conclusions
and adjustment for covariates in each study. A data set based on this
data extraction was created using a spreadsheet program (Microsoft
Excel, Microsoft Co., 2003).
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Statistical analysis
RRs or ORs were used as measures of the association between obesity
and KD. Some cohort studies reported ORs rather than RRs. Since
KD is relatively uncommon, ORs are a good estimate of RR.82 Our
meta-analysis was conducted using STATA 9.0 (StataCorp, College
Station, TX, USA).83 Statistical significance was set at Po0.05.
We created a database by assigning RRs extracted from each
study to their corresponding (or matched) standardized BMI
categories according to the ranges or medians of the reported
BMI categories, using the BMI cutoff points recommended by the
WHO.1,20 When studies did not use WHO cutoff points, we applied
the closest matched ones based on the medians of their BMI
categories. If two or more BMI categories fell into one standardized
BMI category, we pooled the RRs and assigned the combined RR for
that category. For example, a study reported four RRs for BMIo25,
25–27.5, 27.5–30, and BMIX30 kg m2. We pooled the RRs of
25–27.5 and 27.5–30 kg m2 and used the pooled RR to determine
the risk for the 25pBMIo30 kg m2 group. If the range of the
reported BMI category covered two or more standardized categories,
we assigned RR on the basis of the median (or mean) BMI. For
example, if a study reported only one RR for BMIX25 vs BMIo25,
we assigned the RR to 25pBMIo30 kg m2 if the median of this
BMI category was around 27, while if the median was X30 kg m2,
we assigned it to the X30.0 kg m2 group.
We applied both fixed- and random-effects models to estimate
the pooled RRs and 95% CI of KD for each standardized BMI
category compared with normal weight. In the fixed-effects model,
the pooled RR was obtained by averaging the natural logarithm of
RRs (Log(RR)), weighted by the inverse of their respective
variances.84 DerSimonian and Laird’s85 method was used in the
random-effects model to further incorporate between-study varia-
bility. If a significant heterogeneity was present (Po0.05), we
reported the pooled estimates from the random-effects models.
In stratified meta-analyses, we examined potential sources of
heterogeneity, including gender, method of BMI assessment (directly
measured vs self-reported), and KD outcomes. Also, treating BMI as
a continuous variable, we estimated the RR and 95% CI associated
with a 1 unit increase in BMI (kg m2) by using weighted meta-
regression. The regression was weighted by the inverse variance of
the Log(RR) for each category, and we used the median of each BMI
category.
In addition, we assessed publication bias (failure to publish
negative studies) using the Begg’s funnel plots. The RRs were plotted
on a logarithmic scale against their corresponding standard errors
(SEs) for each study.86,87 Studies should be scattered equally above
and below the line showing the pooled estimate of Log(RR) if there
is no publication bias. We also assessed publication bias by two
formal tests: the Begg’s adjusted rank correlation test, and the
Egger’s regression asymmetry test.
Moreover, we calculated PAR for KD for overweight and obesity
based on pooled RRs from our meta-analysis, and the current
estimates of overweight and obesity prevalence in the United States
and other industrialized countries. For the United States, estimates
of prevalence were obtained from nationally representative data
collected in the National Health and Nutrition Examination Survey
2003–2004.70,71 For industrialized countries, estimates conducted by
the International Obesity Task Force were used (RJ Leach, personal
communication, 2006).
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Appendix 1
Characteristics and main findings of three cross-sectional studies and 19 case–control studies on the association between
obesity and KD, by outcome and country of data collection
Reference Country
Subjects, age
(years) Study design
Exposure assessment:
obesity/overweight
(BMI: kg m2) BMI M/Ra Outcome
Main finding:
OR and 95% CI Comments
Otero
et al.47
Spain General
population 237,
47–52
Cross-sectional
study
Obesity: BMIX29 M CKD Univariate analysis 7.70
(2.65–22.3)
No data reported in
multivariate analysis
(1) Obesity was
associated with CKD
(2) No association was
observed in multivariate
analysis
Hallan
et al.48
Norway General
population
69 153, X20
Cross-sectional
study
Underweight: BMI
o18.5
Normal weight: BMI
18.5–24.9b
Overweight: BMI
25–29.9
Obesity:
class I: 30–34.9
class II: 35–39.9
class III: BMIX40
M CKD 1.60 (0.7–3.5) for
underweight
1.02 (0.8–1.4) for
overweight
1.78 (1.4–2.2) for obesity
class I
1.70 (1.1–2.6) for obesity
class II
3.16 (1.5–6.4) for obesity
class III
(1) J-shaped association
between BMI and risk of
CKD
(2) Confounders adjusted
for age, gender, physical
activity, smoking,
diabetes mellitus,
hypertension, and CVD
Vupputuri
et al.49
USA 554 cases, 516
controls, 30–79
Case–control
study
Q1: 15.4–22.9b
Q2: 23.0–25.2
Q3: 25.3–28.4
Q4: BMIX28.5
R ESRD/CKD ESRD 2.7 (0.5–13.9) for
Q2
2.7 (0.5–14.5) for Q3
7.7 (1.5–39.4) for Q4
CKD
1.1 (0.7–1.7) for Q2
1.1 (0.7–1.8) for Q3
1.5 (0.9–2.4) for Q4
(1) Significant association
between higher BMI and
risk of ESRD
(2) Confounders adjusted
for age, ethnicity, gender,
education, smoking,
alcohol, diabetes mellitus,
and hypertension
Pan
et al.50
Canada 21 022 cases,
including 1345
patients with
kidney cancer,
5039 controls,
20–76
Case–control
study
Normal weight
BMIo25b
Overweight
BMI: 25–29.9
Obesity
BMIX30
R Kidney
cancer
Total 1.77 (1.53–2.05)
for overweight
2.74 (2.30–3.25)
for obesity
Men:
2.03 (1.65–2.50)
for overweight
3.15 (2.45–4.05) for
obesity
Women:
1.49 (1.20–1.85)
for overweight
2.42 (1.89–3.09) for
obesity
(1) Significant association
between overweight and
obesity and risk of RCC in
men and women
(2) Confounders adjusted
for age, gender,
residence, education,
smoking, alcohol use,
total caloric intake,
vegetable intake, dietary
fiber intake, exercise
(menopausal status,
number of live births,
menarche age, and age
of first pregnancy also
adjusted in women)
Kreiger
et al.51
Canada 518 cases, 1381
controls, 25–69
Case–control
study
Men:
Q1: BMIp21.5b
Q2: 21.5–23.4
Q3: 23.4–25.1
Q4: BMI425.1
Women:
Q1: BMIp19.7b
Q2: 19.7–21.1
Q3: 21.1–23.0
Q4: BMI423.0
R RCC Men:
1.1 (0.7–1.8) for Q2
1.2 (0.8–1.9) for Q3
1.3 (0.8–2.2) for Q4
Women:
1.2 (0.7–2.0) for Q2
1.7 (1.0–2.9) for Q3
2.5 (1.4–4.6) for Q4
(1) Significant association
between higher BMI and
risk of RCC in females
(2) Confounders adjusted
for age, smoking, and
BMI at age 25
McLaughlin
et al.52
China 154 cases, 157
controls, 35–74
Case–control
study
Men:
Q1:BMIp19.7b
Q2: 19.8–21.9
Q3: 22.0–23.3
Q4: BMI423.3
Women:
Q1:BMIp24.4b
Q2: 24.5–27.4
Q3: 27.4–30.6
Q4: BMI430.6
R RCC Men:
1.4 (0.4–5.0) for Q2
2.7 (0.7–10.9) for Q3
1.7 (0.5–5.7) for Q4
Women:
2.0 (0.5–8.2) for Q2
1.1 (0.2–4.9) for Q3
3.3 (0.7–15.1) for Q4
(1) No association,
maybe due to small
sample size
(2) Confounders adjusted
for age, education, and
smoking
Mellemgaard
et al.53
Denmark 368 cases, 396
controls, 20–79
Case–control
study
Men:
Q1: BMIp23.1
Q2: 23.1–24.5
Q3: 24.5–26.4
Q4: BMI426.4
Women:
Q1: BMIp27.2
Q2: 27.2–29.6
Q3: 29.6–31.7
Q4: BMI431.7
R RCC Men:
1.0 (0.6–1.7) for Q2
1.5 (0.9–2.5) for Q3
1.2 (0.7–2.0) for Q3
Women:
1.0 (0.5–2.0) for Q2
0.8 (0.4–1.7) for Q3
2.2 (1.1–4.2) for Q4
(1) Significant association
in women, but not in
men
(2) Confounders adjusted
for age, smoking, and
SES
Benhamou
et al.54
France 196 cases, 347
controls; mean
(s.d.): 62712
Case–control
study
Q1: BMIp20
Q2: 21–23
R RCC Men:
1.1 (0.5–2.8) for Q2
1.9 (0.8–4.6) for Q3
(1) Significant association
in women, but not in
men
Appendix Table continued on following page
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Reference Country
Subjects, age
(years) Study design
Exposure assessment:
obesity/overweight
(BMI: kg m2) BMI M/Ra Outcome
Main finding:
OR and 95% CI Comments
Q3: 24–26
Q4: BMIX27
2.4 (1.0–5.9) for Q4
Women:
3.0 (1.0–9.1) for Q2
2.9 (0.9–9.3) for Q3
3.5 (1.0–11.8) for Q4
(2) Confounders adjusted
for education and
smoking
Talamini
et al.55
Italy 240 cases, 665
controls, 20–74
Case–control
study
L1: BMIo24b
L2: 24–27
L3: BMI427
R RCC 0.84 (0.59–1.21 for Q2
0.74 (0.51–1.07 for Q3
(1) No association
(2) Confounders adjusted
for age, gender, education,
and area of residence
Mellemgaard
et al.56
International
study:
Australia,
Denmark,
Germany,
Sweden, and
USA
1732 cases, 2309
controls, 20–79
Case–control
study
Men:
L1: BMIo23.1
L2: 23.1–24.8
L3: 24.8–26.6
L4: 26.6–29.0
L5: 29.0–31.0
L6: BMIX31
Women:
L1: BMIo27.3
L2: 27.3–29.7
L3: 29.7–32.7
L4: 32.7–35.5
L5: 35.3–38.1
L6: BMIX38.1
R RCC Men:
1.1 (0.9–1.4) for Q2
1.4 (1.1–1.8) for Q3
1.5 (1.2–2.0) for Q4
1.9 (1.3–2.8) for Q5
1.6 (1.1–2.5) for Q6
Women:
1.0 (0.8–1.4) for Q2
1.3 (1.0–1.8) for Q3
1.5 (1.0–2.1) for Q4
2.7 (1.7–4.3) for Q5
3.6 (2.3–5.7) for Q6
(1) Significant association
in both genders,
especially in women
(2) Confounders adjusted
for age, center, and
smoking
McLaughlin
et al.57
USA 495 cases, 697
controls, 30–64
Case–control
study
Men:
Q1: 14.7–23.6b
Q2: 23.6–25.5
Q3: 25.5–27.9
Q4: 27.9–44.9
Women:
Q1: 16.0–21.6b
Q2: 21.6–23.4
Q3: 23.4–26.2
Q4: 26.2–54.8
R RCC Men:
0.9 (0.6–1.4) for Q2
0.9 (0.6–1.4) for Q3
1.5 (1.0–2.4) for Q4
Women:
1.1 (0.6–2.1) for Q2
1.5 (0.8–2.8) for Q3
2.1 (1.2–3.9) for Q4
(1) Significant association
in women, but not in
men
(2) Confounders adjusted
for age, ethnicity,
smoking, kidney
infection, coffee, tea,
beer, meat consumption,
phenacetin use,
exposure to petroleum,
tar, and pitch products
Goodman
et al.58
USA 267 cases, 267
controls, 20–80
Case–control
study
L1: BMIo24
L2: 24–27
L3: BMIX28
M RCC Total:
1.49 (0.96–2.43) for Q2
2.38 (1.51–4.17) for Q3
Men:
1.93 (1.12–3.77) for Q2
2.67 (1.49–5.94) for Q3
Women:
0.79 (0.31–1.84) for Q2
2.38 (1.15–6.85) for Q3
(1) Significant association
in both genders
(2) Confounders adjusted
for age, gender,
ethnicity, time of
admission, smoking, and
coffee consumption
Yu et al.59 USA 160 cases, 160
controls
15–54
Case–control
study
Q1b lowest quartile
Q2
Q3
Q4 highest quartile
No BMI data reported
R RCC Men:
1.1 (0.4–2.8) for Q2
2.2 (0.9–5.2 for Q3
2.5 (1.0–5.9) for Q4
Women:
1.2 (0.4–4.3) for Q2
1.5 (0.5–5.2) for Q3
3.3 (1.0–11.5) for Q4
(1) Significant association
between BMI 10 years
before diagnosis and risk
of RCC
(2) Cases and controls
matched on gender, age,
ethnicity, and residence
Asal et al.60 USA 315 cases, 649
controls, X20
Case–control
study
Men:
BMIo28.7b
BMIX28.7
Women:
BMIo26.8b
BMIX26.8
R RCC Men: 2.3 (1.4–3.6)
Women: 1.8 (1.1–3.1)
(1) Significant association
in both genders
(2) Confounders adjusted
for age, education in
men; age, smoking in
women
Maclure
et al.61
USA 203 cases, 605
controls, X30
Case–control
study
BMIp28b
BMI428
R RCC Men: 1.7 (1.1–2.8)
Women: 1.7 (0.9–3.2)
(1) Significant association
in men, but not in
women
(2) Confounders adjusted
for age, gender,
education, smoking,
occupation, income,
kidney stone,
hypertension, and CVD
Hiatt et al.62 USA 257 cases, 257
controls; mean
age: 51
Case–control
study
Men:
Q1: BMIo24.6b
Q2: 24.7–25.9
Q3: 26.0–28.2
Q4: BMIX28.3
Women:
Q1: BMIo21.8b
Q2: 21.9–24.5
Q3: 24.6–27.7
Q4: BMIX27.8
M RCC Men
0.9 (0.4–1.8) for Q2
0.9 (0.4–1.9) for Q3
1.4 (0.7–3.1) for Q4
Women:
0.6 (0.2–1.8) for Q2
0.6 (0.2–2.1) for Q3
1.2 (0.4–4.3) for Q4
(1) No association
(2) Confounders adjusted
for age, smoking, kidney
infection, and
hypertension
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Reference Country
Subjects, age
(years) Study design
Exposure assessment:
obesity/overweight
(BMI: kg m2) BMI M/Ra Outcome
Main finding:
OR and 95% CI Comments
Chow et al.63 USA 449 cases, 707
controls, 20–79
Case–control
study
Men:
Q1: BMIp23.1b
Q2: 23.2–24.4
Q3: 24.7–25.8
Q4: 25.8–27.6
Q5: BMIX27.8
Women:
Q1: BMIp26.8b
Q2: 26.9–28.5
Q3: 28.5–30.6
Q4: 30.6–33.7
Q5: BMIX33.8
R RCC Men:
0.8 (0.5–1.2) for Q2
0.8 (0.5–1.4) for Q3
1.1 (0.7–1.7) for Q4
1.2 (0.8–1.8) for Q5
Women:
1.4 (0.6–2.9) for Q2
1.4 (0.6–3.0) for Q3
2.6 (1.3–5.2) for Q4
2.8 (1.5–5.0) for Q5
(1) Significant association
in women, but not in
men
(2) Confounders adjusted
for age, smoking, and
hypertension
Benichou
et al.64
USA 690 cases, 707
controls, 20–79
Case–control
study
Q1b lowest quartile
Q2, Q3, Q4 highest
quartile
Cut points not reported
R RCC Total:
1.1 (0.8–1.7) for Q2
1.3 (0.9–1.8) for Q3
1.6 (1.1–2.3) for Q4
(1) Significant association
(2) Confounders adjusted
for age, gender,
smoking, and
hypertension
Yuan et al.65 USA (SEER) 1204 cases, 1204
controls, 25–74
Case–control
study
L1: BMIo22b
L2: 22.0–23.9
L3: 24.0–25.9
L4: 26.0–27.9
L5: 28.0–29.9
L6: BMIX30
R RCC Total:
1.6 (1.3–2.2) for Q2
1.5 (1.2–2.0) for Q3
1.7 (1.3–2.4) for Q4
2.5 (1.8–3.5) for Q5
4.3 (3.0–6.1) for Q6
Men:
1.7 (1.1–2.5) for Q2
1.6 (1.1–2.4) for Q3
2.0 (1.3–3.1) for Q4
2.7 (1.7–4.3) for Q5
4.6 (2.9–7.5) for Q6
Women:
1.7 (1.1–2.5) for Q2
1.5 (0.96–2.3) for Q3
1.3 (0.7–2.2) for Q4
2.3 (1.2–4.2) for Q5
4.0 (2.3–7.0) for Q6
(1) Significant association
in both genders
(2) Confounders adjusted
for gender, age,
ethnicity, residence, level
of education, smoking,
and use of analgesics
Shapiro et al.66 USA 238 cases, 616
controls, 18–84
Case–control
study
Men:
Q1: BMIo25.4b
Q2: 25.4–27.2
Q3: 27.2–29.5
Q4: BMI429.5
Women:
Q1: BMIo23.4b
Q2: 23.4–26.0
Q3: 26.1–30.1
Q4: BMI430.1
M RCC Men:
1.3 (0.7–2.6) for Q2
1.2 (0.6–2.4) for Q3
2.3 (1.2–4.5) for Q4
Women:
3.1 (1.1–8.3) for Q2
3.0 (1.1–8.0) for Q3
3.3 (1.2–8.7) for Q4
(1) Significant association
in both genders
(2) Confounders adjusted
for age, diabetes
mellitus, and
hypertension
Chiu et al.67 USA 406 cases, 2434
controls, 20–69
Case–control
study
Q1b
Q2
Q3
76–90% Q4–1
91–100% Q4–2
Cut points not reported
R RCC Men:
0.6 (0.3–1.1) for Q2
0.6 (0.3–1.1) for Q3
0.8 (0.4–1.7) for Q4–1
0.4 (0.2–1.0) for Q4–2
Women:
0.5 (0.2–1.4) for Q2
1.0 (0.4–2.5) for Q3
0.7 (0.3–2.1) for Q4–1
2.3 (0.9–6.0) for Q4–2
(1) Significant association
in women, but not in
men
(2) Confounders adjusted
for age, education,
smoking, family history
of kidney cancer, marital
status, energy intake, red
meat, vegetables, and
hypertension
Ramirez
et al.68
Singapore
(NKFS)
General
population
213 873, X18
Cross-sectional
study
BMIo18
BMI 18–22.9b
BMI 23–24.9
BMI 25–27.4
BMI 27.5–29.9
BMIX30
M Protei-
nuria
1.3 (1.0–1.7) for
BMIo18
1.3 (1.2–1.6) for
BMI 25–27.4
1.6 (1.3–1.9) for BMI
27.5–29.9
2.5 (2.2–3.0) for
BMIX30
(1) J-shaped association
between BMI and
proteinuria presence
(2) Confounders adjusted
for age, gender,
ethnicity, diabetes
mellitus, hypertension,
and family history
BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; ESRD, end-stage renal disease; NKFS, National Kidney Foundation
Singapore; OR, odds ratio; RCC, renal cell carcinoma; SEER, the Los Angeles County Cancer Surveillance, Epidemiology and End Results; SES, socioeconomic status.
aM, BMI directly measured; R, BMI self-reported.
bReference group.
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